Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2)

Neurol Sci. 2002 Sep:23 Suppl 2:S51-2. doi: 10.1007/s100720200065.

Abstract

Neuroimaging studies of striatal dopamine transporters (DAT) have shown that this measurement is a specific marker of dopaminergic degeneration in patients with Parkinson's disease. However, little data is available in subjects with early disease onset, particularly in those with autosomal recessive parkinsonism. We measured striatal DAT binding in 10 patients with early onset PD (onset <40 years) and in 10 with late onset PD (onset >50 years) using PET and the tracer [(11)C]FECIT. One early onset subject presented a mutation in the parkin gene consistent with autosomal recessive parkinsonism. Data were compared with those of 15 control subjects. We found a comparable decrement of striatal DAT binding in early and late onset PD. Loss was widespread and bilateral in the patient carrying the Park2 mutation, suggesting a different pattern of denervation in these individuals.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Carbon Radioisotopes
  • Case-Control Studies
  • Corpus Striatum / metabolism*
  • Corpus Striatum / pathology
  • Dopamine Plasma Membrane Transport Proteins
  • Humans
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / metabolism*
  • Middle Aged
  • Mutation
  • Nerve Tissue Proteins*
  • Parkinsonian Disorders / genetics
  • Parkinsonian Disorders / metabolism*
  • Parkinsonian Disorders / pathology
  • Point Mutation
  • Tomography, Emission-Computed* / methods

Substances

  • Carbon Radioisotopes
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • SLC6A3 protein, human